Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Year range
1.
Bol. méd. Hosp. Infant. Méx ; 71(5): 286-291, Sep.-Dec. 2014. ilus, tab
Article in English | LILACS | ID: lil-744079

ABSTRACT

Background: Currently, there is a spreading worldwide tendency to characterize health issues and to propose alternative solutions via the creation of computerized databases. The aim of this study was to present the results in a computerized database of pediatric cardiac surgeries developed under the auspices of the Mexican Association of Specialists in Congenital Heart Diseases (Asociación Mexicana de Especialistas en Cardiopatías Congénitas A.C) and coordinated by the collegiate group of Pediatric Cardiology and Surgery as petitioned by the National Institutes of Health and High Specialty Hospitals Coordinating Commission. Methods: We analyzed all cases registered in the database during a 1-year observation period (August 1, 2011 to July 31, 2012) by all major Health Ministry-dependent institutes and hospitals offering surgical services related to pediatric cardiopathies to the non-insured population. Results: Seven institutions participated voluntarily in completing the database. During the analyzed period, 943 surgeries in 880 patients with 7% reoperations (n = 63) were registered. Thirty-eight percent of the surgeries were performed in children <1 year of age. The five most common cardiopathies were patent ductus arteriosus (n = 96), ventricular septal defect (n = 86), tetralogy of Fallot (n = 72), atrial septal defect (n = 68), and aortic coarctation (n = 54). Ninety percent of surgeries were elective and extracorporeal circulation was used in 62% of surgeries. Global mortality rate was 7.5% with the following distribution in the RACHS-1 score categories: 1 (n = 4, 2%), 2 (n = 19, 6%), 3 (n = 22, 8%), 4 (n = 12, 19%), 5 (n = 1, 25%), 6 (n = 6, 44%), and non-classifiable (n = 2, 9%). Conclusions: This analysis provides a representative view of the surgical practices in cardiovascular diseases in the pediatric population at the national non-insured population level. However, incorporating other health institutions to the national registry database will render a more accurate panorama of the national reality in surgical practices in the population <18 years of age.

2.
Bol. méd. Hosp. Infant. Méx ; 65(2): 121-125, mar.-abr. 2008. ilus, tab
Article in Spanish | LILACS | ID: lil-701142

ABSTRACT

Introducción. Las taquicardias supraventriculares (TSV) son arritmias tratadas con propafenona, debido a su utilidad en población pediátrica. Objetivo: evaluar el efecto antiarrítmico de propafenona, así como su farmacocinética en niños con TSV. Métodos. Se trata de un estudio prospectivo donde se incluyeron niños del servicio de cardiología con diagnóstico de TSV. La evolución clínica de los pacientes fue evaluada mediante monitoreo electrocardiográfico; además, se hizo un estudio farmacocinético de propafenona, utilizando un método de cromatografía de líquidos de alta resolución con detección por fluorescencia. Resultados. Se revisaron los expedientes de 85 niños con diagnóstico de TSV durante el período de 2000 a 2007; actualmente existen 11 pacientes que son tratados con propafenona, y en 3 de ellos se hizo el estudio farmacocinético. El estudio electrocardiográfico mostró trazos normales después del tratamiento con propafenona. Los parámetros farmacocinéticos del medicamento fueron similares a los reportados en estudios previos. Conclusiones. En los pacientes incluidos se observó remisión de la arritmia; además, sus parámetros farmacocinéticos fueron semejantes a los reportados en la literatura, por lo que el uso del medicamento puede ser considerado en niños con dicho padecimiento.


Introduction. Supraventricular tachycardia (SVT) involves arrhythmias treated with propafenone in children due to its utility. The aim of this study was to evaluate the anti-arrhythmic effect of propafenone as well as its pharmacokinetics in children with SVT. Methods. A prospective study was conducted in children with SVT. The evolution of their treatment with propafenone was followed by EKG monitoring. A pharmacokinetic study was carried out by using HPLC with fluorescence detection. Results. The files of 85 children with SVT from 2000 to 2007 were reviewed; currently 11 patients are treated with propafenone, Pharmacokinetics study was performed in 3 of the current patients. The EKG study showed regular registers after propafenone treatment. Propafenone pharmacokinetic parameters were similar to those reported previously. Conclusions. The patients included showed an arrhythmia remission, and their pharmacokinetic parameters were similar to those reported in the literature. Thus, the use of propafenone may be considered appropriate for SVT treatment in children.

SELECTION OF CITATIONS
SEARCH DETAIL